<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065567</url>
  </required_header>
  <id_info>
    <org_study_id>EGME#02-2021</org_study_id>
    <nct_id>NCT05065567</nct_id>
  </id_info>
  <brief_title>Cyclic Vomiting: Droperidol</brief_title>
  <official_title>A Comparison of Haloperidol 5mg IM vs Droperidol 2.5mg and Ondansetron for the Treatment of Hyperemesis in Cyclic Vomiting Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health - Lakeland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health - Lakeland</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two commonly used agents for the treatment of cyclic&#xD;
      vomiting to see if one agent is inferior to the other in time to improvement in symptoms,&#xD;
      need for repeat or rescue medications, treatment failures and complications/side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary outcome</measure>
    <time_frame>2 hours</time_frame>
    <description>will be in change in pain and nausea at 2 hours using a visual analog scale of 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain</measure>
    <time_frame>48 hours</time_frame>
    <description>changes in abdominal pain score at 1, 2, 24, and 48 hours vs. baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nausea</measure>
    <time_frame>48 hours</time_frame>
    <description>change in nausea score at 1, 2, 24, and 48 hours vs. baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success</measure>
    <time_frame>48 hours</time_frame>
    <description>treatment success = both abdominal pain and nausea score &lt; 2 at 2, 24, and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>discharge ready at 2 hours</measure>
    <time_frame>2 hours</time_frame>
    <description>deemed discharge-ready at 2 hours in the opinion of the treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue anti-emetics in ED</measure>
    <time_frame>discharge from ED or 12 hours</time_frame>
    <description>time interval to discharge-ready from t=0(min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Returned to ED</measure>
    <time_frame>7 days</time_frame>
    <description>unscheduled return visits to ED within 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged ED length of stay</measure>
    <time_frame>at discharge from ED or 12 hours</time_frame>
    <description>prolonged ED length of stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cyclic Vomiting Syndrome</condition>
  <arm_group>
    <arm_group_label>haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>droperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droperidol</intervention_name>
    <description>Patients who have been diagnosed with cyclic vomiting syndrome and enrolled in the study will be randomized based on the week to either 2.5mg droperidol IV or haloperidol</description>
    <arm_group_label>droperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Patients who have been diagnosed with cyclic vomiting syndrome and enrolled in the study will be randomized based on the week to either haloperidol</description>
    <arm_group_label>haloperidol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients with clinical diagnosis of cyclic vomiting in the ED&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy, allergy to any of the study medicines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lakeland Regional Healthcare</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelino Mancini, DO, FAOECP</last_name>
      <phone>269-983-4081</phone>
      <email>mmancini@lakelandhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droperidol</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

